SEHK:6855Biotechs
Ascentage Pharma (SEHK:6855) Stock Faces Rising Losses Despite Revenue Growth
Ascentage Pharma Group International came into this print on the back of a weak tape, with the stock down about 21% over three months and closing at HK$32.86 on Friday. The market has been treating the company as a high risk, high expectation biotech story. Today's H1 2026 earnings underline why, with total revenue of ¥302.2m set against a net loss of ¥816.7m and a price to sales multiple of 16.1x that still runs ahead of Hong Kong biotech peers.
Impressed by the revenue traction at Ascentage...